Use of FLIM histology-based HER2-HER3 heterodimer quantification and a Bayesian latent class proportional hazards model to predict cetuximab response in the COIN and new EPOC trials. Retrospective ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results